Another dangerous combination for hypoglycemic coma: Concurrent use of sibutramine and lorazepam [1]

QJM: An International Journal of Medicine

Volumn 101, Issue 3, 2008, Pages 243-245

  Lin, Y Y ^a   Hsu, C W ^a   Chu, S J ^a   Tsai, S H ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LORAZEPAM; SIBUTRAMINE;

ADULT; BODY MASS; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIC COMA; INSOMNIA; LETTER; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 39849105854     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm147     Document Type: Letter

References (22)

1. Fajans SS, Floyd JC Jr. Fasting hypoglycemia in adults. N Engl J Med 1976; 294:766-72.
2. Guldstrand M, Ahren B, Wredling R, Backman L, Lins PE, Adamson U. Alteration of the counterregulatory responses to insulin-induced hypoglycemia and of cognitive function after massive weight reduction in severely obese, subjects. Metabolism 2003; 52:900-7.
3. Jones TW, Porter P, Sherwin RS, Davis EA, O'Leary P, Frazer F, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338:1657-62.
4. Gais S, Born J, Peters A, Schultes B, Heindl B, Fehm HL, et al. Hypoglycemia counterregulation during sleep. Sleep 2003; 26 55-9.
5. Schultes B, Jauch-Chara K, Cais S, Hallschmid M, Reiprich E, Kern W, et al. Defective awakening response to nocturnal hypoglycemia in patients with type 1 diabetes mellitus. PLoS Med 2007; 4:e69.
6. Giordano R, Grottoli S, Brossa P, Pellegrino M, Destefanis S, Lanfranco F, et al. Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. Clin Endocrinol 2003; 59:14-20.
7. Fukagawa K, Sakata T. Monoaminergic anoretic agents. Nippon Yakurigaku Zasshi 2001; 118:303-8.
8. Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonaban. Lancet 2007; 369:71-7.
9. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: Short-term, open-label, observational study. J Hum Hypertens 2005; 19:737-43.
10. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled multicenter trial. Arch Intern Med 2000; 160 2185-91.
11. Karabacak IY, Karabacak O, Toruner FB, Akdemir O, Arslan. M. Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. Gynecol Endocrinol 2004; 19 196-201.
12. Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother 2004; 5:633-42.
13. Sarac-F, Pehlivan M, Celebi G, Saygili F, Yilmaz C, Kabalak T. Effects of sibutramine on thermogenesis in obese patients assessed via immersion, calorimetry. Adv Ther 2006; 23:1016-29.
14. Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007; 369:71-7.
15. Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. Diabetes Obes Metab 2003; 5:338-44.
16. Hung YJ, Chen YC, Pei D, Kuo SW, Hsieh CH, Wu LY, et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type, 2 diabetes. Diabet Med 2005; 22:1024-30.
17. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetess a meta-analysis of clinical studies. Diabetes Care 2005; 28:942-9.
18. Coletta DR, Bates SH, Jones RB, Bailey CJ. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. Diab Vasc Dis Res 2006; 3:186-8.
19. Deeg MA, Lipkin EW. Hypoglycemia associated with the use of fluoxetine. West J Med 1996; 164:262-3.
20. Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001; 35:1371-4.
21. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56:128-36.
22. Warnock JK, Biggs F. Nefazodone-induced hypoglycemia in a diabetic patient with major depression. Am J Psychiatry 1997; 154 288-9.